| Basics |
uniQure N.V. Ordinary Shares
uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
|
| IPO Date: |
March 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.33B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.66 | 2.93%
|
| Avg Daily Range (30 D): |
$1.35 | 4.51%
|
| Avg Daily Range (90 D): |
$1.23 | 3.67%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.62M |
| Avg Daily Volume (30 D): |
3.61M |
| Avg Daily Volume (90 D): |
3.28M |
| Trade Size |
| Avg Trade Size (Sh.): |
92 |
| Avg Trade Size (Sh.) (30 D): |
91 |
| Avg Trade Size (Sh.) (90 D): |
87 |
| Institutional Trades |
| Total Inst.Trades: |
3,013 |
| Avg Inst. Trade: |
$1.64M |
| Avg Inst. Trade (30 D): |
$2.08M |
| Avg Inst. Trade (90 D): |
$1.88M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.96M |
| Avg Closing Trade (30 D): |
$4.42M |
| Avg Closing Trade (90 D): |
$4.03M |
| Avg Closing Volume: |
95.73K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-1.38
|
$-.69
|
|
Diluted EPS
|
|
$-1.38
|
$-.69
|
|
Revenue
|
$
|
$ 3.7M
|
$ 5.26M
|
|
Gross Profit
|
$
|
$ 3.3M
|
$ 4.61M
|
|
Net Income / Loss
|
$
|
$ -80.53M
|
$ -37.72M
|
|
Operating Income / Loss
|
$
|
$ -51.04M
|
$ -43.87M
|
|
Cost of Revenue
|
$
|
$ .4M
|
$ .66M
|
|
Net Cash Flow
|
$
|
$ 343.28M
|
$ 36.61M
|
|
PE Ratio
|
|
|
|
|
|
|
